Nautilus Q2 net loss $14.5M; first revenue $0.2M; delays broadscale assay, accelerates proteoforms

Nautilus Biotechnology, Inc.

Revenue of $0.2M from MJFF grant and first Early Access customer; net loss $14.5M vs $15.0M YoY.
Operating expenses $15.9M, down 7% YoY; cash, equivalents and investments $129.2M.
Voyager platform pre-orders expected early 2027, shipments mid-2027; proteoform kits GA mid-2027.
Broadscale assay delayed; no 2027 GA timeline; company reallocating resources to proteoforms.
AKT1 proteoform assay Early Access late 2026; second oncology assay mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.